Why the study?
In crenarchaea, dedicated ring nucleases degrade cA4 to deactivate CRISPR ancillary ribonucleases once viral infection is cleared, but the equivalent enzyme had not been identified in bacteria.
The study identifies TTHB144 as the first example of a self-limiting CRISPR ribonuclease, providing a mechanism for deactivating the ribonuclease once viral infection is cleared in bacteria.
No immediate clinical implications for cardiovascular care; leaves open engineering of self-limiting CRISPR tools.
Cyclic oligoadenylate (cOA) secondary messengers are generated by type III CRISPR systems in response to viral infection. cOA allosterically activates the CRISPR ancillary ribonucleases Csx1/Csm6, which degrade RNA non-specifically using a HEPN (Higher Eukaryotes and Prokaryotes, Nucleotide binding) active site. This provides effective immunity but can also lead to growth arrest in infected cells, necessitating a means to deactivate the ribonuclease once viral infection has been cleared. In the crenarchaea, dedicated ring nucleases degrade cA₄ (cOA consisting of 4 AMP units), but the equivalent enzyme has not been identified in bacteria. We demonstrate that, in Thermus thermophilus HB8, the uncharacterized protein TTHB144 is a cA₄-activated HEPN ribonuclease that also degrades its activator. TTHB144 binds and degrades cA₄ at an N-terminal CARF (CRISPR-associated Rossman fold) domain. The two activities can be separated by site-directed mutagenesis. TTHB144 is thus the first example of a self-limiting CRISPR ribonuclease.
No takes yet. Share an insight, caveat, or question.
Athukoralage et al. (2019) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: